[1]郁明玮,游 卉.基于NF-κB/TGF-β1通路研究宫腔粘连2号方对大鼠宫腔粘连的影响[J].陕西中医,2025,46(5):589-593.[doi:DOI:10.3969/j.issn.1000-7369.2025.05.003]
　YU Mingwei,YOU Hui.Effects of Gongqiang Zhanlian-2 prescription on intrauterine adhesions was studied based on NF-κB/TGF-β1 pathway[J].,2025,46(5):589-593.[doi:DOI:10.3969/j.issn.1000-7369.2025.05.003]
点击复制

基于NF-κB/TGF-β1通路研究宫腔粘连2号方对大鼠宫腔粘连的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年5期
页码:
589-593
栏目:
基础研究
出版日期:
2025-05-05

文章信息/Info

Title:
Effects of Gongqiang Zhanlian-2 prescription on intrauterine adhesions was studied based on NF-κB/TGF-β1 pathway
作者:
郁明玮1; 2; 3; 游 卉1; 2; 3
(1.湖南中医药大学第一附属医院,湖南 长沙 410007; 2.湖南中医药大学,湖南 长沙 410208; 3.尤昭玲全国名中医传承工作室,湖南 长沙 410007)
Author(s):
YU Mingwei1; 2; 3; YOU Hui1; 2; 3
(1.The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine,Changsha 410007,China; 2.Hunan University of Chinese Medicine,Changsha 410208,China; 3.YOU Zhaoling National Famous Traditional Chinese Medicine Inheritance Studio,Changsha 410007,China)
关键词:
宫腔粘连;  宫腔粘连2号方;  NF-κB/TGF-β1信号通路;  尤昭玲;  白介素-6
Keywords:
Intrauterine adhesions;  Gongqiang Zhanlian-2 prescription;  NF-κB/TGF-β1 signaling pathway;  YOU Zhaoling;  IL-6
分类号:
R 711.74
DOI:
DOI:10.3969/j.issn.1000-7369.2025.05.003
文献标志码:
A
摘要:
目的:研究宫腔粘连2号方治疗宫腔粘连(IUA)的机制。方法:通过机械联合感染双重损伤法复制IUA大鼠模型。10只大鼠为一组,随机将60只大鼠分为假手术组、模型组、戊酸雌二醇组(补佳乐组)、宫腔粘连2号方低、中、高剂量组。灌胃21 d后,肉眼观察大鼠子宫的外观变化。同时,利用HE染色测定内膜的厚度和腺体数,以Masson染色评估内膜纤维化面积。通过Western blot检测NF-κB和TGF-β1的表达情况,并利用ELISA检测血清IL-6和TNF-α的水平。结果: ELISA检测结果显示:与假手术组比较,各组TNF-α、IL-6浓度升高,差异有统计学意义(P<0.01)。与模型组比较,宫腔粘连2号方、补佳乐组TNF-α、IL-6浓度下降,差异有统计学意义(P<0.01)。与模型组比较,宫腔粘连2号方各组呈剂量依赖性下降,其中中剂量组与补佳乐组表达水平比较无统计学差异(P>0.05)。Western blot检测结果显示:与假手术组比较,各组TGF-β1、NF-κB蛋白表达水平上调,差异有统计学意义(P<0.01)。与模型组比较,宫腔粘连2号方、补佳乐组TGF-β1、NF-κB蛋白表达水平下调,差异有统计学意义(P<0.01)。与模型组比较,宫腔粘连2号方各组呈剂量依赖性下调,其中中、高剂量组与补佳乐组表达水平无统计学差异(P>0.05)。结论:宫腔粘连2号方有可能通过抑制细胞内NF-κB和TGF-β1的表达,降低IL-6和TNF-α的水平,改善宫腔粘连。
Abstract:
Objective:To study the mechanism of Gongqiang Zhanlian-2 prescription in the treatment of IUA.Methods:IUA rat model was reproduced.Ten rats were divided into one group and 60 rats were randomly divided into six groups.The rats were treated by mechanical infection combined with double injury.These groups were sham operation group,model group,estradiol valerate group(Bujiale group),low,medium and high dose groups of Gongqiang Zhanlian-2 prescription.After 21 days of intragastric administration,the appearance of rat uterus was observed by naked eye.At the same time,the intimal thickness and number of glands were measured by HE staining,and the fibrosis area was evaluated by Masson staining.The expressions of NF-κB and TGF-β1 were detected by Western blot,and serum levels of IL-6 and TNF-α were detected by ELISA.Results:ELISA results showed that compared with sham operation group,the concentrations of TNF-α and IL-6 in all groups increased significantly(P<0.01).Compared with the model group,the concentrations of TNF-α and IL-6 in Gongqiang Zhanlian-2 prescription and Bujiale groups decreased significantly(P<0.01).Compared with model group,Gongqiang Zhanlian-2 prescription decreased in a dose-dependent manner in each group,and there was no significant difference in expression level between medium dose group and Bujiale group(P>0.05).Western blot analysis showed that compared with the sham operation group,the expression levels of TGF-β1 and NF-κB in all groups were up-regulated,and the differences were significant(P<0.01).Compared with model group,the protein expression levels of TGF-β1 and NF-κB in Gongqiang Zhanlian-2 prescription and Bujiale groups were down-regulated,and the differences were significant(P<0.01).Compared with model group,Gongqiang Zhanlian-2 prescription was down-regulated in a dose-dependent manner,and there was no significant difference in expression level between medium and high dose groups and western medicine group(P>0.05).Conclusion:Gongqiang Zhanlian-2 prescription may reduce the levels of IL-6 and TNF-α by inhibiting the expression of NF-κB and TGF-β1 in cells,and improve the progression of intrauterine adhesion.

参考文献/References:

[1] LEE W L,LIU C H,CHENG M,et al.Focus on the primary prevention of intrauterine adhesions:Current concept and vision[J].Int J Mol Sci,2021,22(10):100101.
[2] AAGL.Practice report:Practice guidelines on intrauterine adhesions developed in collaboration with the european society of gynaecological endoscopy(esgw)[J].Gynecol Surg,2017,14(1):6.
[3] 中华医学会妇产科学分会.宫腔粘连临床诊疗中国专家共识[J].中华妇产科杂志,2015,50(12):881-887.
[4] CAO M,PAN Y,ZHANG Q,et al.Predictive value of live birth rate based on different intrauterine adhesion evaluation systems following tcra[J].Reprod Biol Endocrinol,2021,19(1):13.
[5] 关艳杰.中重度宫腔粘连病因及治疗研究进展[J].陕西医学杂志,2020,49(2):254-257.
[6] HOOKER A B,MANSVELDER F J,ELBERSl R.Reproductive outcomes in women with mild intrauterine adhesions:A systematic review and meta-analysis[J].J Matern Fetal Neonatal Med,2022,35(25):6933-6941.
[7] 王蓓茹,许越,吴建军.中医角度认识宫腔粘连病因病机及临床诊治[J].医学理论与实践,2021,34(10):1656-1658.
[8] 阳媛,毛艳华,王佳,等.机械和感染双重法建立中华田园犬宫腔粘连模型[J].重庆医科大学学报,2017,42(4):401-405.
[9] PUENTE G E,ALONSO P L,VEGA J A,et al.Intrauterine infusion of platelet-rich plasma for severe asherman syndrome:A cutting-edge approach[J].Updates Surg,2021,73(6):2355-2362.
[10] SANTAMARIA X,LIU J H,AGHAJANOVA L,et al.Should we consider alternative therapies to operative hysteroscopy for the treatment of asherman syndrome?[J].Fertil Steril,2020,113(3):511-521.
[11] 汤彪,万虹.经阴道超声诊断宫腔粘连的研究进展[J].保健医学研究与实践,2023,20(S2):244-246.
[12] BENOR A,GAY S,DECHERNEY A.An update on stem cell therapy for asherman syndrome[J].J Assist Reprod Genet,2020,37(7):1511-1529.
[13] 邢艺璇,吴阳,唐诗,等.尤昭玲辨治宫腔粘连求子经验[J].中国中医药信息杂志,2021,28(1):133-136.
[14] 周亚儿,孙运明.宫腔镜下冷刀分离术治疗宫腔粘连的疗效比较[J].浙江创伤外科,2025,30(1):102-104.
[15] 崔妙雅,马丽,张湘燕,等.Smad7在TGF-β1/Smads通路介导的肺纤维化中的研究进展[J].现代医药卫生,2020,36(4):535-538.
[16] LIU L,CHEN G,CHEN T,et al.SI-snhg5-foxf2 inhibits TGF-β1-induced fibrosis in human primary endometrial stromal cells by the wnt/β-catenin signalling pathway[J].Stem Cell Res Ther,2020,11(1):479.
[17] CHAPMAN H A,WEI Y,MONTAS G,et al.Reversal of TGFβ1-driven profibrotic state in patients with pulmonary fibrosis[J].N Engl J Med,2020,382(11):1068-1070.
[18] 邓祥丽,陈丽娟,邵梅,等.益肺汤调控TGF-β1/Smad2通路抗肺纤维化机制研究[J].陕西中医,2024,45(4):435-439.
[19] 闫文瑞,张常喜,张晓晋,等.通心络胶囊调控转化生长因子-β1表达改善糖尿病心肌病大鼠心肌纤维化损伤机制研究[J].陕西中医,2023,44(12):1683-1687,1697.
[20] 黄紫纯,雷磊,匡继林.丹参酮ⅡA通过TGF-β1/PI3K/Akt信号通路对子宫内膜间质细胞纤维化的影响[J].中华中医药杂志,2024,39(2):903-906.
[21] XUE X,CHEN Q,ZHAO G,et al.The overexpression of TGF-β and CCN2 in intrauterine adhesions involves the NF-κB signaling pathway[J].PLoS One,2015,10(12):e0146159.
[22] KONCI R,CAMINSKY N,TULANDI T,et al.Supplements to conventional treatment after hysteroscopic lysis of intrauterine adhesions:A systematic review[J].J Obstet Gynaecol Can,2020,42(8):984-1000.
[23] 李灿宇,党秋红,刘欢欢,等.TGF-β1和Smad4在中重度宫腔粘连组织中的表达及临床意义[J].中国妇产科临床杂志,2018,19(4):347-349.
[24] NING J,ZHANG H,YANG H.Microrna326 inhibits endometrial fibrosis by regulating TGF-β1/smad3 pathway in intrauterine adhesions[J].Mol Med Rep,2018,18(2):2286-2292.
[25] 李姗,周志文,刘湘花,等.黄杞苷干预NF-κB信号通路抑制巨噬细胞炎症反应及氧化应激[J].中国感染控制杂志,2023,22(4):383-390.
[26] 彭艳芳,张莹雯,赵映前,等.紫檀芪对肺纤维化大鼠NF-κB/TGF-β1/smad 3信号通路的影响[J].天津中医药大学学报,2019,38(1):53-58.
[27] FAN Z,QI X,YANG W,et al.Melatonin ameliorates renal fibrosis through the inhibition of NF-κB and TGF-β1/smad3 pathways in db/db diabetic mice[J].Arch Med Res,2020,51(6):524-534.

相似文献/References:

[1]闫晓彤,朱 婷,章晓乐,等.补肾活血方联合补佳乐对宫腔粘连大鼠YAP1/TGF-β1信号通路的影响[J].陕西中医,2022,(8):987.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.001]
　YAN Xiaotong,ZHU Ting,ZHANG Xiaole,et al.Effect of Bushen Huoxue decoction combined with Progynova on YAP1/TGF-β1 pathway in intrauterine adhesions rats[J].,2022,(5):987.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.001]
[2]郑维维,杜子琪,陈 怡,等.归肾丸加减联合T管治疗宫腔粘连术后疗效研究[J].陕西中医,2022,(12):1729.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.018]
　ZHENG Weiwei,DU Ziqi,CHEN Yi,et al.Clinical efficacy study on modified Guishen Wan combined with T tube for postoperative intrauterine adhesions[J].,2022,(5):1729.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.018]

备注/Memo

备注/Memo:
[基金项目]湖南省自然科学基金资助项目(2025JJ80972); 湖南省重点研发项目(2023SK2050); 湖南省中医药科研计划重点项目(C2022012); 国家中医药管理局尤昭玲全国名中医传承工作室建设项目
更新日期/Last Update: 2025-05-08